Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
TAILORx
About the Trial
The Trial Assigning Individualized Options for Treatment enrolled 10,273 women with hormone receptor positive, HER2 negative, node negative breast cancer and assigned treatment by 21 gene recurrence score. Women with midrange scores 11 to 25 were randomized to endocrine therapy alone or plus chemotherapy. Chemotherapy showed no overall benefit in this group, although some women aged 50 or younger with scores of 16 to 25 had a small benefit. The results indicated that roughly 70 percent of women with this type of cancer derived little benefit from chemotherapy. TAILORx rapidly changed practice, reducing chemotherapy use and its toxicity and cost. It is the clearest demonstration of genomic testing driving de escalation of cancer treatment.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...